Type 2 Diabetes Drug Study Showed Improvement In Alzheimer’s Patients

Highlights:

Diabetes treating drugs by its triple mode of action significantly improved memory loss in a study carried out in Alzheimer’s disease by a research team of Lancaster University in the U.K.
The novel approach reduces the problems in growth factor signaling which is found to be the cause of brain degeneration in Alzheimer’s patients.
Promises effective therapy in patients with a chronic neurodegenerative disease by delivering constant neuroprotective effects.

Study about Alzheimer's response to Diabetes drugs

Study published in Brain Research showed that the drugs which are developed to treat type 2 diabetes might offer considerable improvement in treating Alzheimer's disease (AD). The drug used in the study further demonstrated a significant reversal of memory loss by its triple mode of action. Benefits of the triple agonist drugs are found in the clinical study, carried out in transgenic mice by using a maze test.

The cognitive function involving learning and memory found to be improved by the drug which also exhibits certain neuroprotective properties.

Alzheimers Disease
Alzheimer''s disease is a progressive neurodegenerative disease affecting memory and thinking and making the person increasingly dependent on others.

‘Clinical investigation of an older version of drugs showed much efficacy in treating Alzheimer’s disease by exhibiting triple agonist effect. This study helps discover new drugs for treating incurable diseases in future.’

These include the following:

Protects the nerve cell by increasing the levels of growth factor in brain
Amyloid plaques in the brain associated with Alzheimer's are decreased
Decreasing oxidative stress and chronic inflammation
Delaying the rate of neuronal loss

Triple Receptor Drugs

Drugs used in the study act at various pathways helps in protecting the brain against degeneration. It is found that problems related to growth factors (GLP-1, GIP, and Glucagon) results in the impairment in the brain of Alzheimer's disease patients. Diabetes drugs used in the clinical study showed enhanced levels of brain growth factor resulting in a reversal of memory loss by exhibiting steady neuroprotective effects.

Liraglutide a diabetic drug also showed better results in spatial memory with an overall reduced plaque in the brain. The study showed that liraglutide was not only beneficial in early stages of an AD, but also in later stages. This was proven when the effects are compared with liraglutide treated mice with saline-treated mice. However, the study requires further deeper research in human by studying dose-response and comparison with other drugs making it a potential treatment for Alzheimer's disease.

Alzheimer's Disease

Alzheimer's is the most common form of dementia that results in problems in thinking, memory, and behavior. It occurs gradually at increasing age and the majority of people with Alzheimer's are above 65 and the disease gets worse over time. In the United States alone, nearly 200,000 people are diagnosed with early onset of Alzheimer's disease and estimated to be the six leading cause of death.

Type 2 Diabetes
Globalization and changing lifestyles has made diabetes very common in developing countries so much so that India is known as the Diabetes Capital of the World.

Currently, there is no cure for Alzheimer's but there are various on-going researches worldwide aimed at delaying the onset, prevention, and treatment of the disease.

What are the Symptoms of Alzheimer's Disease?

The symptoms of Alzheimer's includes

Serious memory loss
Confusion about events, place and time
Behavioural changes
Mood disorders
Difficulty in walking and speaking
Illogical suspicion
Disorientation

References :

Liraglutide can reverse memory impairment, synaptic loss and reduce plaque load in aged APP/PS1 mice, a model of Alzheimer's disease. - (https://www.ncbi.nlm.nih.gov/pubmed/23973293)
What Is Alzheimer's? - (https://www.alz.org/alzheimers_disease_what_is_alzheimers.asp)

Source: Medindia

Liraglutide [rDNA] Injection
This medication is a glucagon-like peptide (GLP)-1 receptor agonist, prescribed for type 2 diabetes.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

APA

Vijayaganesh Kasinathan. (2018, January 03). Type 2 Diabetes Drug Study Showed Improvement In Alzheimer’s Patients. Medindia. Retrieved on Aug 18, 2022 from https://www.medindia.net/news/healthinfocus/type-2-diabetes-drug-study-showed-improvement-in-alzheimers-patients-175973-1.htm.
MLA

Vijayaganesh Kasinathan. "Type 2 Diabetes Drug Study Showed Improvement In Alzheimer’s Patients". Medindia. Aug 18, 2022. <https://www.medindia.net/news/healthinfocus/type-2-diabetes-drug-study-showed-improvement-in-alzheimers-patients-175973-1.htm>.
Chicago
Vijayaganesh Kasinathan. "Type 2 Diabetes Drug Study Showed Improvement In Alzheimer’s Patients". Medindia. https://www.medindia.net/news/healthinfocus/type-2-diabetes-drug-study-showed-improvement-in-alzheimers-patients-175973-1.htm. (accessed Aug 18, 2022).
Harvard
Vijayaganesh Kasinathan. 2021. Type 2 Diabetes Drug Study Showed Improvement In Alzheimer’s Patients. Medindia, viewed Aug 18, 2022, https://www.medindia.net/news/healthinfocus/type-2-diabetes-drug-study-showed-improvement-in-alzheimers-patients-175973-1.htm.